Papers:
Development of Nanoconjugate with Different Monoclonal Antibodies to Inhibit Molecular Targets Important for Tumor Angiogenesis
Fujita M., Khazenzon N.M., Lee B-S, Holler E., Black K.L., Ljubimova J.Y., Cedars-Sinai Medical Center, US
Tumor cell-specific drug targeting is the major goal of nanotechnology-based platforms. A nanoconjugate Polycefin was synthesized for targeted delivery of antisense oligonucleotides and antibodies into tumors. The delivery of antisense oligonucleotides to α4 and β1 [...]
Characterization and in vivo efficacy of targeted nanoparticles for systemic siRNA delivery to tumors
This abstract highlights the results from our latest work in the design and application of targeted nanoparticles for systemic siRNA delivery. Over the past several years, we have performed extensive physicochemical and biological characterization of [...]
Development of a specific micro/nanodevice validating the concept of molecular biopsy
The nanomedicine concept implies early detection at the molecular level and molecular characterisation to implement a specific therapy. In this context, the development of micro/nanotool devoted for intra-tissular characterisation is indispensable. We first demonstrated that [...]
Sirna Nanomedicines for Cancer Gene Therapy
We developed a polyelectrolyte complex (PEC) micelle-based delivery system for treatment of prostate cancer. A PEGylated siRNA targeting human vascular endothelial growth factor (hVEGF) was synthesized. The hVEGF expression was almost completely inhibited in vitro [...]
Journal: TechConnect Briefs
Volume: 2, Technical Proceedings of the 2007 NSTI Nanotechnology Conference and Trade Show, Volume 2
Published: May 20, 2007
Industry sector: Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 1-4200-6183-6